IPO Journey
Picard Medical, Inc.
IPO Date: May 6, 2026 · 14 filings tracked
Final Offer Terms
Ticker
PMI
Exchange
NYSE American
Offer Price
$0.30
Shares Offered
16,666,667
Estimated Proceeds
$5.0M
Expected Listing
May 06, 2026
Underwriters
Led by WestPark Capital, Inc.
Filing Timeline
1
S-1
April 1, 2025
- Sole U.S. and Canadian provider of an FDA-approved Total Artificial Heart
- Proven clinical efficacy with a 70% one-year patient survival rate
2
S-1/A
April 25, 2025
- Sole provider of FDA-approved Total Artificial Heart (TAH) in U.S. and Canada
- Proven track record with over 2,100 patients treated
3
S-1/A
May 9, 2025
- Sole provider of FDA-approved total artificial heart systems in the U.S. and Canada
- Proven track record with over 2,100 clinical cases since 1985
4
S-1/A
May 23, 2025
- Sole manufacturer of the only FDA-approved total artificial heart in the U.S. and Canada
- Proven clinical track record with over 2,100 successful implants since 1985
5
S-1/A
July 14, 2025
- Sole provider of the only FDA-approved total artificial heart (TAH) in the U.S. and Canada
- Developing the 'Emperor' internal heart to eliminate external power tubes
Changes from previous filing
- ▸ Expected offer range: $3.5 – $4.5 per share
- ▸ Shares offered: 4,250,000
- ▸ Estimated proceeds: $14M
- ▸ Underwriters: Westpark Capital, Inc., Uphorizon, LLC, Sentinel Brokers Company, Inc.
6
S-1/A
July 18, 2025
- Owns SynCardia Systems, the only FDA-approved Total Artificial Heart provider in the U.S. and Canada.
- Proven track record with over 2,100 successful implants performed to date.
Changes from previous filing
- ▸ Exchange: New York Stock Exchange American
7
S-1/A
July 30, 2025
- Sole manufacturer of the only FDA-approved Temporary Total Artificial Heart (TAH).
- Strong competitive moat due to high regulatory and manufacturing barriers to entry.
Changes from previous filing
- ▸ Exchange: NYSE American
8
S-1/A
August 6, 2025
- Sole provider of the only FDA-approved Total Artificial Heart (TAH) in the U.S. and Canada
- Proven track record with over 2,100 successful implants performed to date
9
424B4
Material Update
September 2, 2025
- Owns the only FDA-approved device for replacing both failing heart ventricles.
- Proven track record with over 2,100 implants performed across 27 countries.
Changes from previous filing
- ▸ Exchange: New York Stock Exchange American, LLC
- ▸ Price range removed
- ▸ Final offer price: $4.0 per share
- ▸ Estimated proceeds: $17M
- ▸ Underwriters: Westpark Capital, Inc., Sentinel Brokers Company, Inc.
10
S-1
January 12, 2026
- Owns SynCardia, the only FDA-approved Total Artificial Heart (TAH) device.
- Proven track record with over 2,100 patients treated across 27 countries.
Changes from previous filing
- ▸ Exchange: NYSE American
- ▸ Shares offered: 17,000,000
11
S-1/A
February 4, 2026
- Owns SynCardia, the only FDA-approved Total Artificial Heart (TAH) in the U.S.
- Provides a critical, life-saving bridge for end-stage heart failure patients awaiting transplants.
Changes from previous filing
- ▸ Ticker symbol removed
12
S-1
April 27, 2026
- Sole provider of FDA-approved Total Artificial Heart (TAH) in the U.S. and Canada
- Proven track record with over 2,100 successful implants worldwide
13
S-1/A
May 1, 2026
- Owns SynCardia, the only FDA-approved Total Artificial Heart in the U.S. and Canada
- Proven clinical track record with over 2,100 implants performed worldwide
424B4
Final Pricing
May 6, 2026
- Owns SynCardia, the only FDA-approved Total Artificial Heart (TAH) in the U.S. and Canada.
- Proven life-saving technology utilized in over 2,100 patients worldwide.
Changes from previous filing
- ▸ Ticker symbol: PMI
- ▸ Exchange: NYSE American
- ▸ Final offer price: $0.3 per share
- ▸ Shares offered: 16,666,667
- ▸ Estimated proceeds: $5M
- ▸ Underwriters: WestPark Capital, Inc.
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.